Mural Oncology plc

Mural Oncology — Investor Day (September 2024)

59 slides from Mural Oncology's investor day presentation, Sep 26, 2024

  1. Slide 1: 2024 Virtual Investor Day: Clinical Insights & Clinician Discussion

    2024 virtual investor day: Clinical insights & clinician discussion September 26, 2024 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,” “may,” “will” and similar expressions are intended

  3. Slide 3: Highly Experienced Late-Stage Oncology Team

    Highly Experienced Late-Stage Oncology Team Executive Team Caroline Loew, PhD CEO Vicki Goodman, MD CMO Maiken Keson-Brookes CLO Adam Cutler CFO Board of Directors Francis Cuss MB, BChir, FRCP Scott Jackson MBA – Chairman Caroline Loew PhD George Golumbeski PhD Sachiyo Minegishi MBA Benjamin Hickey

  4. Slide 4: Mural at a Glance

    Mural at a Glance Abbrev.: CM: cutaneous melanoma; IL-12: interleukin-12; IL-18: interleukin-18; MM: mucosal melanoma; OS: overall survival; PDR: preliminary data readout; PROC: platinum resistant ovarian cancer; RP2D: recommended phase 2 dose; TLR: topline results Subject to event accrual Subject t

  5. Slide 5: Nemvaleukin: Engineered to unlock the efficacy potential of High Dose IL-2

    Nemvaleukin: Engineered to unlock the efficacy potential of High Dose IL-2 for more patients High dose (HD) IL-2 (PROLEUKIN©/aldesleukin) has proven curative potential in melanoma and RCC Extremely durable complete responses However toxic AE profile requires administration in an acute care setting,

  6. Slide 6: Pipeline Overview: 2024-2025 Milestones

    Pipeline Overview: 2024-2025 Milestones Discovery Preclinical Phase 1 Phase 2 Phase 3 Indication Dosing Nemvaleukin (IV) Combination with Pembrolizumab (Potentially Registrational) Platinum Resistant Ovarian Cancer (PROC) (ARTISTRY-7) Nemvaleukin (IV) Monotherapy (Potentially Registrational) Mucosal

  7. Slide 7: Today's Agenda

    Today’s Agenda Nemvaleukin clinical proof of concept Monotherapy and combination therapy across broad range of solid tumors Unmet need in platinum-resistant ovarian cancer Current treatment options and gaps ARTISTRY-7 overview: PROC Trial design, powering assumptions, progress update Mucosal melanom

  8. Slide 8: Nemvaleukin Alfa: Clinical Proof of Concept

    Ulka Vaishampayan, md University of michigan Nemvaleukin ALFA: CLINICAL PROOF OF CONCEPT

  9. Slide 9: ARTISTRY-1: First-In-Human Trial of IV Nemvaleukin

    ARTISTRY-1: First-In-Human Trial of IV Nemvaleukin Global, Multicenter, Open-Label Phase 1/2 Trial Dose Expansion NCTO2799095 1. Patients from Parts A and B could roll over to Part C upon progression or stable disease (after > 4 cycles) on monotherapy 2. Nemvaleukin daily Q5D, then off treatment for

  10. Slide 10: Clinical Pharmacodynamic Effects of Nemvaleukin Distinct from HD IL-2

    Clinical Pharamacodynamic Effects of Nemvaleukin are Distinct from HD IL-2, Preferentially Expanding Only Cytotoxic CD8+ T Cells and NK Cells Nemvaleukin data are from the 6 μg/kg cohort in Part A of ARTISTRY-1. For fold change plots, data are mean + SE (N=10). For time course plot, data are mean +

  11. Slide 11: ARTISTRY-1: Durable Monotherapy Responses in Melanoma (Part B)

    Responses per RECIST v1.1 ARTISTRY-1: Nemvaleukin Demonstrated Durable Monotherapy Responses in Melanoma (Part B) Alla,b (n=46) Mucosal (n=6) Best overall response, n (%) CR 0 0 PR 6 (13.0)c 2 (33.3)d ORR, n (%) [95% CI] 6 (13.0) [4.9-26.3]c 2 (33.3) [4.3-77.8]d DOR in weeksd, Mean (SD) Median (rang

  12. Slide 12: Case Study: 66-Year-Old Female with Urethral Melanoma (1 of 2)

    Case Study: 66-Year-Old Female with Urethral Melanoma (1 of 2) + per RECIST criteria Artistry-1 Data cut off Aug 2, 2023, EAP cut-off July 2024 Dx On-Study Benefits Prior Treatment Change in Target Lesions from Baseline+ Cycle 2 Stable Disease (SD): 8% increase Cycle 4 SD: 17% reduction Cycle 6-55 P

  13. Slide 13: Case Study: Urethral Melanoma (2 of 2): Target Lesion Shrinkage

    Case Study: 66-Year-Old Female with Urethral Melanoma (2 of 2): Target Lesion Shrinkage M1 EAP study Data cutoff July 2024 Mar 2020 Best response PR April 2017 66 y/o F dx of mucosal melanoma Sep 2017 – Sep 2018 Adjuvant nivolumab Nemvaleukin 6 μg/kg 2019 2018 2021 Sep 2019 Last documented PD 2020 A

  14. Slide 14: ARTISTRY-1: Durable Monotherapy Responses in RCC (Part B)

    ARTISTRY-1: Nemvaleukin Demonstrated Durable Monotherapy Responses in RCC (Part B) Responses per RECIST v1.1. CABO, cabozantinib; CPI, checkpoint inhibitor; CR, complete response; DCR, disease control rate (CR+PR+SD); DOR, duration of response; IPI, ipilimumab; mo, months; NIVO, nivolumab; ORR, over

  15. Slide 15: ARTISTRY-1: Combination with Pembrolizumab Demonstrated Durable Responses

    ARTISTRY-1: Nemvaleukin Combination Treatment with Pembrolizumab Demonstrated Durable Responses Data cut off Mar 27, 2023 1. DOR data cut off Sept 27, 2023 Abbrev.: BEV: bevacizumab; CBP: carboplatin; CDDP: cisplatin; CR: complete response; DOC: docetaxel; FDA: Food and Drug Administration; GEM: gem

  16. Slide 16: Case Study: 48-Year-Old Female with High-Grade Serous Ovarian Cancer

    Case Study: 48-Year-Old Female with High-Grade Serous Ovarian Cancer BEV=bevacizumab, CBP=carboplatin, CDDP=cisplatin, GEM=gemcitabine. Dx in Aug 2014 On-Study Benefits Prior Treatment High Grade Serous Ovarian Cancer Jan. 7, 2019 – termination of study (On treatment ~52 months)* Nemvaleukin + pembr

  17. Slide 17: Case Study: 83-Year-Old Female with High-Grade Serous Ovarian Cancer

    Case Study: 83-Year-Old Female with High-Grade Serous Ovarian Cancer OC2 Dx Oct 2008 On-Study Benefits Prior Treatment High Grade Serous Ovarian Cancer Feb 2020 – April 2022 (On treatment ~26+ months) Nemvaleukin + pembrolizumab therapy 3 µg/kg IV Nemvaleukin ARTISTRY-1 Treatment Target Lesions (Axi

  18. Slide 18: Nemvaleukin's Adverse Event Profile in ARTISTRY-1

    Nemvaleukin’s Adverse Event Profile in ARTISTRY-1 Was Consistent with Our Expectations Based on its Mechanism of Action Dose expansion: monotherapy (Part B) and combination therapy (Part C) Data as of March 27, 2023 Administered on outpatient basis; most frequent AEs were manageable with supportive

  19. Slide 19: Unmet Need in Platinum-Resistant Ovarian Cancer

    John hays, md, phd The ohio state university comprehensive cancer center Unmet need in platinum-resistant ovarian cancer

  20. Slide 20: Platinum Resistant Ovarian Cancer (PROC)

    Platinum Resistant Ovarian Cancer (PROC) Ovarian cancer is the second most common gynecologic malignancy but most common cause of gynecologic cancer death in US (~20-25K cases per year) No commonly agreed upon early detection test 75% of patients diagnosed at advanced stage (Stage III-IV) Primary tr

  21. Slide 21: What do we do when patients recur?

    What do we do when patients recur? Oronsky et al Med Onc 2017 Med Oncol 2017 Jun;34(6):10

  22. Slide 22: Platinum Resistance

    Platinum Resistance Almost all patients who recur will become platinum resistant… Aurelia Chemotherapy w/wo bevacizumab Improved PFS but not OS Pujade-Loraine JCO 2014 May 1;32(13):1302-8

  23. Slide 23: Antibody Drug Conjugates

    Antibody Drug Conjugates Two new approvals in last 2 years Mirvetuximab Sorevtansine (FRa) Trastuzumab Deruxtecan (HER2) What about the last 10 years? Moore et al Annals of Oncology Volume 32, Issue 6, June 2021, Pages 757-765 Meric Burnstam et al JCO 2024 Jan 1;42(1):47-58.

  24. Slide 24: What about the last years? Many agents tested

    What about the last 10 years? Many agents tested: Immune therapy Checkpoint inhibitors (PD1/PD-L1, CTLA4, TIGIT, etc…) Novel antigen delivery/recognition (NY-ESO, CA125) Bispecific T-Cell Engagers (BiTE) CAR-T/TCR Underwhelming performance 10-15% RR for single agents Increased for combinations (e.g.

  25. Slide 25: What About the Future?

    What About the Future? ADCs are great, but… Limited population with marker FRa high – 30-60% HER2 2/3+ – 30% IO therapy has promise but monotherapy has limitations Smart combinations are the way forward

  26. Slide 26: ARTISTRY-7 Overview

    Vicki goodman, md chief medical officer Artistry-7 overview

  27. Slide 27: ARTISTRY-1: Combination Treatment with Pembrolizumab Demonstrated Durable Responses

    ARTISTRY-1: Nemvaleukin Combination Treatment with Pembrolizumab Demonstrated Durable Responses Data cut off Mar 27, 2023 1. DOR data cut off Sept 27, 2023 Abbrev.: BEV: bevacizumab; CBP: carboplatin; CDDP: cisplatin; CR: complete response; DOC: docetaxel; FDA: Food and Drug Administration; GEM: gem

  28. Slide 28: ARTISTRY-7: Phase 3 Potentially Registrational Study for PROC

    ARTISTRY-7: Phase 3 / Potentially Registrational Study for Platinum-Resistant Ovarian Cancer Pembrolizumab may be administered up to 35 cycles. Investigational Nemvaleukin IV + Pembrolizumab versus Chemotherapy Key eligibility criteria Platinum-resistant/refractory epithelial ovarian, fallopian tube

  29. Slide 29: ARTISTRY-7: Futility Criteria for Monotherapy Arms

    ARTISTRY-7: Futility Criteria for Monotherapy Arms Smaller Single Agent Arms to Assess Contribution of Components Futility criteria for Arm 2: Based on Keynote-100 trial, where single agent pembro was evaluated in 376 patients with PROC with a response rate of 8% Futility in ARTISTRY-7 trial defined

  30. Slide 30: ARTISTRY-7: Enrollment and Statistical Assumptions

    ARTISTRY-7: Enrollment and Statistical Assumptions Arm 4 Investigator's Choice Single-Agent Chemotherapy PLD IV, 40 mg/m2 (Day 1 of 28-day cycle) Paclitaxel IV, 80 mg/m2 (Days 1, 8, 15, and 22 of 28-day cycle) Topotecan IV, 4 mg/m2 (Days 1, 8, and 15 of 28-day cycle) Gemcitabine IV, 1000 mg/m2 (Days

  31. Slide 31: ARTISTRY-7 Interim Analysis Readout Expected Late Q1 or Early Q2 2025

    ARTISTRY-7 Interim Analysis Readout Expected Late Q1 or Early Q2 2025 Events: ~215 events for interim analysis estimated by late Q4 2024 or early Q1 2025 Data Readout: OS IA readout in late Q1 or early Q2 2025 EVENTS AND STATISTICS # of Events: Protocol specified interim analysis (IA) for overall su

  32. Slide 32: ARTISTRY-7 Interim Analysis: Potential Outcomes

    ARTISTRY-7 Interim Analysis (IA): Potential Outcomes 1 2a 2b IA Readout Q1 or early Q2 2025 Next Steps Hazard Ratio Meets Bar for Success Study Declared Positive File BLA for PROC in 2025 Decision to Continue to Final Analysis Decision to Terminate Study Hazard Ratio Not Met File BLA for PROC in 202

  33. Slide 33: Mucosal Melanoma & the Need for Dedicated Treatments

    RICH CARVAJAL, md Northwell health cancer institute MUCOSAL MELANOMA & THE NEED FOR DEDICATED TREATMENTS

  34. Slide 34: Mucosal Melanoma: A Rare Melanoma Subtype

    Mucosal Melanoma: A Rare Melanoma Subtype Melanoma in Non-Sun Damaged Skin Melanoma in Sun Damaged Skin Acral Melanoma Mucosal Melanoma Conjunctival Melanoma 80% <10% <5% <2% <1% Uveal Melanoma <5%

  35. Slide 35: The Clinical Heterogeneity of Mucosal Melanoma

    The Clinical Heterogeneity of Mucosal Melanoma Carvajal RD et al. JNCCN 2012. Prasad et al. Head and Neck 2006. Head and Neck Mucosa (55%) Location Nasal Cavity, 49% Lateral nasal wall Turbinates Paranasal Sinuses, 10% Maxillary sinus Ethmoid sinus Oral Cavity, 41% Hard palate Upper alveolus Symptom

  36. Slide 36: CheckMate: OS with Nivolumab by Subtype

    CheckMate 172 (n=1008): OS with Nivolumab by Subtype Subtype n Median OS (mos) Non-Acral Cut Melanoma 723 25.3 (95% CI, 20.9 – 28.9) Ocular Melanoma 103 12.6 (95% CI, 10.2 – 15.1) Mucosal Melanoma 63 11.5 (95% CI, 6.4 – 15.0) Acral Melanoma 55 25.8 (95% CI, 15.1 – 30.6) Other 64 21.8 (95% CI, 9.8 –

  37. Slide 37: International Real World Data Experience

    International Real World Data Experience (n = 545) Dimitriou F et al. Ann Oncol, 2022. Data on patients from 25 centers in Australia, Europe, USA and Asia Median follow-up of 31 months (95% CI, 17-54) Progression-Free Survival Overall Survival

  38. Slide 38: Most Recent FDA Approvals by Indication

    Most Recent FDA Approvals by Indication Cutaneous Melanoma Lifileucel (February 2024) Basal Cell Ca Cemiplimab (Feb 2021) Merkel Cell Ca Retifanlimab (March 2023) cSCC Pembrolizumab (June 2019) Acral Melanoma None Mucosal Melanoma None Uveal Melanoma Hepzato Kit (Aug 2023) FDA Approvals for Melanoma

  39. Slide 39: Completed Clinical Trials in Mucosal Melanoma Setting

    Completed Clinical Trials in Mucosal Melanoma Setting Study Phase n Treatment Arm(s) Results Neoadjuvant Mao et al, ASCO 2023 2 19 Lenvatinib + Pembro 32% path RR in resected population (n=15) Lian et al, Ann Oncol 2024 2 29 Toripalimab + Axitinib 33% path RR in resected population (n=24) Adjuvant L

  40. Slide 40: Limited Guidelines Available to Guide Management

    Limited Guidelines Available to Guide Management Smith HG et al. Eur J Cancer, 2020. NCCN Guidelines, Head and Neck Cancers. Nenclares et al. Eur J Cancer, 2020. Sinonasal and Oral Cavity Melanoma Anorectal and Vulvovaginal Melanoma

  41. Slide 41: How do we manage advanced disease?

    How do we manage advanced disease? Appropriate clinical trial if available CPI as SOC front-line therapy Targeted therapy as next line if actionable alteration present Carbo/Taxol/Bev Other chemotherapy regimens

  42. Slide 42: Summary

    Summary Mucosal melanoma is a rare melanoma subset with a distinct biology and a particularly poor prognosis There is no proven effective therapy in the perioperative or metastatic settings Only limited efforts are ongoing that are focused on developing novel therapies specifically for mucosal melan

  43. Slide 43: ARTISTRY-6 Overview

    Vicki goodman, md chief medical officer Artistry-6 overview

  44. Slide 44: Systematic Literature Review of Post-Anti-PD-(L)1 Advanced Mucosal Melanoma

    Systematic Literature Review of Outcomes and Treatments in Post-Anti-PD-(L)1 Advanced Mucosal Melanoma Systematic Literature Review (SLR) conducted to identify interventional and real-world (RW) studies assessing treatments and clinical outcomes in patients with advanced mucosal melanoma who have pr

  45. Slide 45: ARTISTRY-1: Durable Monotherapy Responses in Melanoma (Part B)

    Responses per RECIST v1.1 ARTISTRY-1: Nemvaleukin Demonstrated Durable Monotherapy Responses in Melanoma (Part B) Alla,b (n=46) Mucosal (n=6) Best overall response, n (%) CR 0 0 PR 6 (13.0)c 2 (33.3)d ORR, n (%) [95% CI] 6 (13.0) [4.9-26.3]c 2 (33.3) [4.3-77.8]d DOR in weeksd, Mean (SD) Median (rang

  46. Slide 46: ARTISTRY-6 Cohort 2: Trial of Nemvaleukin in Mucosal Melanoma

    Cohort 2 of ARTISTRY-6: Phase 2 - Potentially Registrational Trial of Nemvaleukin in Mucosal Melanoma https://clinicaltrials.gov, NCT04830124 Key eligibility criteria 1 Unresectable and/or metastatic mucosal melanoma Patient has received anti–PD(L)-1 ± anti–CTLA-4 therapy No more than 1 prior system

  47. Slide 47: ARTISTRY-6 Cohort 2: Assumptions on Final Data

    ARTISTRY-6 Cohort 2: Assumptions on Final Data Cohort 2 of ARTISTRY-6 study expected to provide the most robust clinical dataset in advanced mucosal melanoma to date Primary analysis will occur when all patients have a minimum follow up of at least 6 months Target response rate: 25% We believe a res

  48. Slide 48: Engineered IL-18 Program

    Jean Chamoun, phD VICE PRESIDENT, RESEARCH Engineered il-18 program

  49. Slide 49: IL-18 is a Potent Stimulator of Innate and Adaptive Immunity, but with Key Limitations

    Activates NK cells and antigen-experienced CD8+ T cells Restores activity in dysfunctional T cells Matures dendritic cells (DCs) IL-18R IL-18R MYD88 IL-18 Suppressed activity IL-18R IL-18R IL-18 IL-18BP IL-18BP IL-18BP overexpressed in the TME IL-18BP binds strongly to IL-18 minimizing it’s sign

  50. Slide 50: Mural Solution: Engineer an IL-18 with Optimized Characteristics

    Mural Solution: Engineer an IL-18 with Optimized Characteristics NK / CD8+ T / DCs IL-18R IL-18R IL-18v IL-18BP IL-18BP-rich TME Engineer an active IL-18 molecule unaffected by IL-18BP presence Engineer an IL-18 with and extended half-life Optimize the IL-18 potency to fit its newly engineered pro

  51. Slide 51: No Binding of Mural Oncology Variants to IL-18BP

    --No Binding-- IL-18 huMOv1 IL-18 huMOv2 No Binding of Mural Oncology Variants to IL-18BP Broad Range of Potency Enhanced Pharmacokinetics Native HuIL-18 tight binding to IL18-BP No binding of MOV to IL18-BP huMOv1/2/3- human Mural Oncology variants IL18BP-resistant, half-life enhanced Preclinical S

  52. Slide 52: Enhanced Pharmacokinetic Extended Pharmacodynamic

    Enhanced Pharmacokinetic Extended Pharmacodynamic muMOv1-mouse Mural Oncology variant IL18BP-resistant, half-life enhanced Mural’s Approach Achieves Intended Half-Life and Associated Pharmacodynamics Effects

  53. Slide 53: Complete Responses and Survival Improvement in IL-18 Mouse Ortholog Variant

    Complete Responses and Survival Improvement Seen in Mural’s IL-18 Mouse Ortholog Variant Agent Dose (mg/kg) % TGI* Day 21 Complete Response Day 50 Probability of Survival Day 50 muMOv1 2.56 86% 2/10 40% muMOv1 5.12 93% 4/10 50% muMOv1 7.68 92% 5/10 50% *%TGI = % tumor growth inhibition, calculated b

  54. Slide 54: Key Takeaways: IL-18

    Key Takeaways: IL-18 Mural’s fit-for-purpose approach successfully engineered an IL-18 molecule with the desired profile: Maximal resistance to IL18-BP binding Enhance half-life compared to native IL-18 Optimized potency Clearly demonstrated desired efficacy with mouse ortholog variant IND filing by

  55. Slide 55: Why Mural & Why Now?

    CAROLINE LOEW, pHd WHY MURAL & WHY NOW?

  56. Slide 56: Mural at a Glance

    Mural at a Glance Abbrev.: CM: cutaneous melanoma; IL-12: interleukin-12; IL-18: interleukin-18; MM: mucosal melanoma; OS: overall survival; PDR: preliminary data readout; PROC: platinum resistant ovarian cancer; RP2D: recommended phase 2 dose; TLR: topline results Subject to event accrual Subject t

  57. Slide 57: Key Takeaways: ARTISTRY-7 Trial Design Assumptions and Progress

    Key Takeaways: ARTISTRY-7 Trial Design Assumptions and Progress Fully enrolled with 456 patients (versus 448 planned), with approximately 187 patients per experimental arm Futility analysis complete for monotherapy arms: Pembrolizumab monotherapy arm reached futility (defined as <2 confirmed CR or P

  58. Slide 58: Key Takeaways: ARTISTRY-6 Cohort 2 Trial Assumptions and Progress

    Key Takeaways: ARTISTRY-6 Cohort 2 Trial Assumptions and Progress Cohort 2 or ARTISTRY-6 study expected to provide the most robust clinical dataset in advanced mucosal melanoma to date Fully enrolled with 92 patients Target response rate: 25% Response rate of 20-25% would be meaningful for patients

  59. Slide 59: Q&A

    Q&A

Mural Oncology — Investor Day (September 2024) on 6ix